KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Receivables (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Receivables data on record, last reported at $5.7 billion in Q4 2025.

  • For Q4 2025, Receivables fell 7.58% year-over-year to $5.7 billion; the TTM value through Dec 2025 reached $5.7 billion, down 7.58%, while the annual FY2025 figure was $5.7 billion, 7.58% down from the prior year.
  • Receivables reached $5.7 billion in Q4 2025 per REGN's latest filing, up from $5.7 billion in the prior quarter.
  • Across five years, Receivables topped out at $7.0 billion in Q2 2021 and bottomed at $4.2 billion in Q1 2021.
  • Average Receivables over 5 years is $5.5 billion, with a median of $5.6 billion recorded in 2025.
  • Peak YoY movement for Receivables: soared 753.18% in 2021, then dropped 26.25% in 2022.
  • A 5-year view of Receivables shows it stood at $5.5 billion in 2021, then fell by 2.26% to $5.3 billion in 2022, then increased by 6.35% to $5.7 billion in 2023, then increased by 9.61% to $6.2 billion in 2024, then decreased by 7.58% to $5.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $5.7 billion in Q4 2025, $5.7 billion in Q3 2025, and $5.6 billion in Q2 2025.